Authors’ Notes: The information in this document was transcribed by Jayne Dixon Weber from a webinar by Craig Erickson, MD. It has been reviewed by Robert Miller, Elizabeth Berry-Kravis, MD, PhD, Randi Hagerman, MD, Nicole Tartaglia, MD, Reymundo Lozano, MD, Carol Delahunty, MD, and by the members of the Fragile X Clinical & Research Consortium.
This document was originally authored in 2012 by Gudrun Aubertin, MD, Jeremy Turk, MD, Andrew Levitas, MD, Jeannie Visootsak, MD, Carol Delahunty, MD, and Elizabeth Berry‐Kravis, MD, PhD.
The Fragile X Clinical & Research Consortium was founded in 2006 and exists to improve the delivery of clinical services to families impacted by any Fragile X-Associated Disorder and to develop a research infrastructure for advancing the development and implementation of new and improved treatments. Please contact us below for more information.